Aligos Therapeutics Inc — Quarterly Financial Statistics (NASDAQ:ALGS) | MetaTrader

Open full chart

Financials

Overview 声明 Statistics Dividends

Quarterly Annual

Cash from operating activities -20.1 M-18.4 M-20.91 M-15.5 M-24.34 M -79.16 M Cash from investing activities 10.4 M19.97 M-44.07 M-39.42 M47.68 M -15.83 M Cash from financing activities -4 00097 K101.74 M-177 K-53 K 101.61 M Free cash flow -20.1 M-18.4 M-20.91 M-15.5 M-24.34 M -79.16 M

新闻

H.C. Wainwright维持Aligos Therapeutics股票买入评级，看好pevifoscorvir研发进展

Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress

Aligos Therapeutics股价因乙肝二期研究进展而上涨

Aligos Therapeutics stock rises on Phase 2 HBV study progress

Aligos公布乙肝药物二期研究进展

Aligos reports progress on Phase 2 hepatitis B drug study

Aligos Therapeutics任命James Hassard为首席商务官

Aligos therapeutics appoints James Hassard as chief commercial officer

UBS以肝脏疾病管线为由给Aligos Therapeutics股票首次评级为"买入"

Aligos Therapeutics stock initiated with Buy rating at UBS on liver disease pipeline

Aligos报告THR-β激动剂协同减重效果

Aligos reports synergistic weight loss effect with THR-β agonist